Oncocyte Corp Files 8-K: Material Agreement & Financials
Ticker: IMDX · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1642380
Sentiment: neutral
Topics: material-agreement, financial-reporting, corporate-update
TL;DR
Oncocyte Corp filed an 8-K on 4/5/24 detailing a material agreement and financial updates.
AI Summary
On April 5, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported other events and filed financial statements and exhibits. This 8-K filing provides updates on the company's corporate activities and financial reporting.
Why It Matters
This filing indicates significant corporate actions and financial reporting by Oncocyte Corporation, which could impact investors' understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- April 5, 2024 (date) — Date of earliest event reported
- California (jurisdiction) — State of incorporation
- 1-37648 (company_id) — Commission File Number
- 27-1041563 (company_id) — IRS Employer Identification No.
- 15 Cushing Irvine, California 92618 (address) — Address of principal executive offices
- 949-409-7600 (phone_number) — Business phone number
FAQ
What is the nature of the Material Definitive Agreement entered into by Oncocyte Corporation on April 5, 2024?
The filing indicates the entry into a Material Definitive Agreement on April 5, 2024, but the specific details of this agreement are not provided in the excerpt. Further review of the full filing is required to understand its nature.
What other events are reported in this 8-K filing?
Besides the material definitive agreement, the filing also notes 'Other Events' and the submission of 'Financial Statements and Exhibits'.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on April 11, 2024.
What is Oncocyte Corporation's principal executive office address?
Oncocyte Corporation's principal executive office is located at 15 Cushing Irvine, California 92618.
What is Oncocyte Corporation's fiscal year end?
Oncocyte Corporation's fiscal year ends on December 31.
Filing Stats: 908 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2024-04-11 17:28:54
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 16KB
- 0001493152-24-014355.txt ( ) — 231KB
- ocx-20240405.xsd (EX-101.SCH) — 3KB
- ocx-20240405_lab.xml (EX-101.LAB) — 33KB
- ocx-20240405_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: April 11, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer